Enzalutamide‐induced severe thrombocytopenia complicated by a seizure in a 76‐year‐old man with castration‐resistant prostate cancer. Issue 1 (31st October 2018)

• Record Type: Journal Article
• Authors: Murata, Masaki; Takizawa, Itsuhiro; Maruyama, Ryo; Kasahara, Takashi; Hara, Noboru; Tomita, Yoshihiko
• Is Part Of: IJU case reports. Volume 2:Issue 1(2019)
• Page Start: 9
• Page End: 11
• Publication Date: 2018-10-31
• Subjects: castration‐resistant prostate cancer -- enzalutamide -- seizure -- severe adverse event -- thrombocytopenia; Urology -- Periodicals; Genitourinary organs -- Periodicals; Electronic journals; Periodicals; 616.6
• DOI: 10.1002/iju5.12025
• Languages: English
• ISSNs: 2577-171X

Abstract

Abstract : Introduction: Adverse events with enzalutamide widely used for men with castration‐resistant prostate cancer are of interest. Case presentation: A 76‐year‐old man developed castration‐resistant prostate cancer. He received 160 mg of enzalutamide daily. On the 13th day after treatment, severe thrombocytopenia was observed (platelet count: 1.9 × 10 4 /μL). Normal coagulation and fibrinolytic systems suggested thrombocytopenia induced by enzalutamide. Enzalutamide was withdrawn immediately, and platelet count uneventfully recovered to 7.0 × 10 4 /μL and 28.8 × 10 4 /μL 9 and 30 days after discontinuation, respectively. He restarted enzalutamide therapy without thrombocytopenia recurrence. However, 81 days after restarting enzalutamide, he experienced a seizure. There were no significant findings from brain computed tomography, which suggested that the seizure was also an enzalutamide‐associated adverse event. Conclusion: Thrombocytopenia may occur early following enzalutamide therapy, and blood analysis within 2 weeks after treatment may facilitate its management. Enzalutamide‐induced thrombocytopenia, complicated by seizure, has not been reported.